» Articles » PMID: 15143919

Telomerase Activity and Telomerase Catalytic Subunit in Hepatocellular Carcinoma

Overview
Specialty Gastroenterology
Date 2004 May 18
PMID 15143919
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: Telomerase activation has been found in most malignant tumors. Human telomerase reverse transcriptase is a catalytic subunit of human telomerase and a rate-limiting factor of the enzymatic activity of telomerase. The present study was designed to examine the usefulness of detecting human telomerase catalytic subunit mRNA and telomerase activity as a molecular diagnostic marker for human liver cancers.

Methodology: Thirty-one specimens of hepatocellular carcinoma and corresponding adjacent tissues were analyzed for human telomerase reverse transcriptase expression by reverse transcription polymerase chain reaction and for telomerase activity by polymerase chain reaction-based telomeric repeat amplification protocol.

Results: Human telomerase reverse transcriptase mRNA expression was observed in 97% of hepatocellular carcinoma tissues, in contrast none of the non-tumorous liver tissues did. Telomerase activity was detected in 94% of hepatocellular carcinoma and in only 16% of adjacent liver tissues. Human telomerase reverse transcriptase mRNA expression and telomerase activity were observed in all 3 grade I (well-differentiated) hepatocellular carcinoma. Significant correlations between human telomerase reverse transcriptase mRNA expression and hepatocellular carcinoma and also between telomerase activity and HCC were found (both p<0.001).

Conclusions: The results indicate that human telomerase catalytic subunit mRNA expression and telomerase activity might be associated with hepatocellular carcinogenesis and could be as markers for diagnosis of hepatocellular carcinoma.

Citing Articles

Regulation of expression of drug-metabolizing enzymes by oncogenic signaling pathways in liver tumors: a review.

Braeuning A, Schwarz M Acta Pharm Sin B. 2020; 10(1):113-122.

PMID: 31993310 PMC: 6976994. DOI: 10.1016/j.apsb.2019.06.013.


Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma.

Pezzuto F, Buonaguro L, Buonaguro F, Tornesello M Infect Agent Cancer. 2017; 12:27.

PMID: 28529542 PMC: 5437489. DOI: 10.1186/s13027-017-0138-5.


Novel plasma telomerase detection method to improve cancer diagnostic assessment.

Hilal G, Reitzel R, Hamal Z, Chaftari A, Al Wohoush I, Jiang Y PLoS One. 2017; 12(5):e0174266.

PMID: 28467443 PMC: 5414931. DOI: 10.1371/journal.pone.0174266.


Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.

Pezzuto F, Izzo F, Buonaguro L, Annunziata C, Tatangelo F, Botti G Oncotarget. 2016; 7(34):54253-54262.

PMID: 27276713 PMC: 5342339. DOI: 10.18632/oncotarget.9801.


Telomere and telomerase in chronic liver disease and hepatocarcinoma.

Carulli L, Anzivino C World J Gastroenterol. 2014; 20(20):6287-92.

PMID: 24876749 PMC: 4033466. DOI: 10.3748/wjg.v20.i20.6287.